To further investigate the effects of IBTK in tumor growth in the presence of a functional immune system, we utilized a CT26 xenograft tumor model and found that immunocompetent mice implanted with IBTK-KD CT26 cells exhibited reduced tumor growth in vivo (Figure 4—figure supplement 3G–I). Here, DDX53 is linked to neoplasm.